Baker Avenue Asset Management’s 10x Genomics TXG Stock Holding History

Baker Avenue Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.34M	Sell	35,024 -2,902	-8%	-$76.1K	0.03%	257
2026 Q1	$805K	Buy	37,926 +2,299	+6%	+$46K	0.02%	313
2025 Q4	$581K	Buy	35,627 +7,925	+29%	+$120K	0.01%	344
2025 Q3	$324K	Buy	27,702 +8,044	+41%	+$105K	0.01%	462
2025 Q2	$228K	Buy	+19,658	New	+$179K	0.01%	448
2023 Q4	–	Sell	-110	Closed	-$4.54K	–	1414
2023 Q3	$4.54K	Buy	110 +92	+511%	+$4.79K	﹤0.01%	966
2023 Q2	$1K	Hold	18	–	–	﹤0.01%	1176
2023 Q1	$1K	Buy	18 +10	+125%	+$467	﹤0.01%	1177
2022 Q4	$292	Buy	+8	New	+$262	﹤0.01%	1513

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baker Avenue Asset Management's TXG Position: Q2 2026 in Review

Baker Avenue Asset Management reduced its 10x Genomics (TXG) stake by 7.7% in Q2 2026, selling an estimated $76.1K and leaving 35,024 shares worth $1.34M. The position accounts for 0.03% of the portfolio, ranked #257.

Baker Avenue Asset Management first reported a position in TXG in Q4 2022 and has held it in 9 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Baker Avenue Asset Management held 35,024 shares of 10x Genomics worth $1.34M as of Q2 2026.
Baker Avenue Asset Management sold 2,902 10x Genomics shares in Q2 2026, an estimated $76.1K.
10x Genomics made up 0.03% of Baker Avenue Asset Management's portfolio in Q2 2026, its #257 holding.
Baker Avenue Asset Management first reported a position in 10x Genomics in Q4 2022 and has held it in 9 quarters since.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.